Molecular Docking Reveals Ivermectin and Remdesivir As Potential Repurposed Drugs Against SARS-CoV-2

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2021 Mar 22

PMID 33746908

Citations 42

Authors

Ahmad F Eweas

Amr A Alhossary

Ahmed S Abdel-Moneim

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2 is a newly emerged coronavirus that causes a respiratory disease with variable severity and fatal consequences. It was first reported in Wuhan and subsequently caused a global pandemic. The viral spike protein binds with the ACE-2 cell surface receptor for entry, while TMPRSS2 triggers its membrane fusion. In addition, RNA dependent RNA polymerase (RdRp), 3'-5' exoribonuclease (nsp14), viral proteases, N, and M proteins are important in different stages of viral replication. Accordingly, they are attractive targets for different antiviral therapeutic agents. Although many antiviral agents have been used in different clinical trials and included in different treatment protocols, the mode of action against SARS-CoV-2 is still not fully understood. Different potential repurposed drugs, including, chloroquine, hydroxychloroquine, ivermectin, remdesivir, and favipiravir, were screened in the present study. Molecular docking of these drugs with different SARS-CoV-2 target proteins, including spike and membrane proteins, RdRp, nucleoproteins, viral proteases, and nsp14, was performed. Moreover, the binding affinities of the human ACE-2 receptor and TMPRSS2 to the different drugs were evaluated. Molecular dynamics simulation and MM-PBSA calculation were also conducted. Ivermectin and remdesivir were found to be the most promising drugs. Our results suggest that both these drugs utilize different mechanisms at the entry and post-entry stages and could be considered potential inhibitors of SARS-CoV-2 replication.

Citing Articles

Predicting the Anti-SARS-CoV-2 Potential of Isoquinoline Alkaloids from Brazilian Siparunaceae Species Using Chemometric Tools.

Gomes B, Fernandes D, Mendonca S, Campos M, da Fonseca T, Constant L Int J Mol Sci. 2025; 26(2).

PMID: 39859347 PMC: 11765762. DOI: 10.3390/ijms26020633.

Bioinformatics and molecular biology tools for diagnosis, prevention, treatment and prognosis of COVID-19.

Meira D, Zetum A, Casotti M, Campos da Silva D, de Araujo B, Vicente C Heliyon. 2025; 10(14):e34393.

PMID: 39816364 PMC: 11734128. DOI: 10.1016/j.heliyon.2024.e34393.

drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor.

Hussein D, Almatrafi A, Gomaa M, Alhowsawi A, Almustafa S, Alsaihaty H F1000Res. 2024; 12:1452.

PMID: 39474132 PMC: 11519612. DOI: 10.12688/f1000research.131508.2.

Exploring 7β-amino-6-nitrocholestens as COVID-19 antivirals: , synthesis, evaluation, and integration of artificial intelligence (AI) in drug design: assessing the cytotoxicity and antioxidant activity of 3β-acetoxynitrocholestane.

Shahabuddin , Uzma , Azam M, Parveen M, Kadir N, Min K RSC Med Chem. 2024; .

PMID: 39430952 PMC: 11485945. DOI: 10.1039/d4md00257a.

Computational investigation of novel synthetic analogs of C-1'β substituted remdesivir against RNA-dependent RNA-polymerase of SARS-CoV-2.

Cardoza S, Singh A, Sur S, Singh M, Dubey K, Samanta S Heliyon. 2024; 10(17):e36786.

PMID: 39286185 PMC: 11402944. DOI: 10.1016/j.heliyon.2024.e36786.

References

Ivanov K, Thiel V, Dobbe J, van der Meer Y, Snijder E, Ziebuhr J . Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J Virol. 2004; 78(11):5619-32. PMC: 415832. DOI: 10.1128/JVI.78.11.5619-5632.2004. View

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J . Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020; 6(10):1192-1198. PMC: 7185795. DOI: 10.1016/j.eng.2020.03.007. View

Abdel-Moneim A, Abdelwhab E . Evidence for SARS-CoV-2 Infection of Animal Hosts. Pathogens. 2020; 9(7). PMC: 7400078. DOI: 10.3390/pathogens9070529. View

Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G . Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv. 2020; . PMC: 7263509. DOI: 10.1101/2020.05.15.098731. View

Lehrer S, Rheinstein P . Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo. 2020; 34(5):3023-3026. PMC: 7652439. DOI: 10.21873/invivo.12134. View

Xu X, Liu Y, Weiss S, Arnold E, Sarafianos S, Ding J . Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 2003; 31(24):7117-30. PMC: 291860. DOI: 10.1093/nar/gkg916. View

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P . Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020; 27(3):325-328. PMC: 7154514. DOI: 10.1016/j.chom.2020.02.001. View

Kwiek J, Haystead T, Rudolph J . Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry. 2004; 43(15):4538-47. DOI: 10.1021/bi035923w. View

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. PMC: 7262788. DOI: 10.1056/NEJMoa2007764. View

10.

Ma Y, Wu L, Shaw N, Gao Y, Wang J, Sun Y . Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci U S A. 2015; 112(30):9436-41. PMC: 4522806. DOI: 10.1073/pnas.1508686112. View

11.

Yang S, Atkinson S, Wang C, Lee A, Bogoyevitch M, Borg N . The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020; 177:104760. DOI: 10.1016/j.antiviral.2020.104760. View

12.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

13.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

14.

Eckerle L, Becker M, Halpin R, Li K, Venter E, Lu X . Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 2010; 6(5):e1000896. PMC: 2865531. DOI: 10.1371/journal.ppat.1000896. View

15.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

16.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

17.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

18.

Sali A, Blundell T . Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993; 234(3):779-815. DOI: 10.1006/jmbi.1993.1626. View

19.

Zhao L, Jha B, Wu A, Elliott R, Ziebuhr J, Gorbalenya A . Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe. 2012; 11(6):607-16. PMC: 3377938. DOI: 10.1016/j.chom.2012.04.011. View

20.

Mugisha C, Vuong H, Puray-Chavez M, Bailey A, Fox J, Chen R . A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2 Growth in Cell Culture. mSphere. 2020; 5(5). PMC: 7471006. DOI: 10.1128/mSphere.00658-20. View